Inhibikase Therapeutics Increases Equity Plan Shares by 3M

Inhibikase Therapeutics, Inc. held its 2026 Annual Meeting, where stockholders approved an amendment to the 2020 Equity Incentive Plan, increasing the authorized shares reserved for issuance by 3,000,000. Additionally, shareholders approved an amendment to the Certificate of Incorporation to limit the liability of certain officers, elected two Class III directors, and ratified CohnReznick LLP as the independent auditor. Stockholders also approved executive officer compensation on an advisory basis and determined to hold future advisory votes on executive compensation annually.